Arcus Biosciences Inc (NYSE:RCUS)
$ 15.27 -0.56 (-3.54%) Market Cap: 1.40 Bil Enterprise Value: 417.63 Mil PE Ratio: 0 PB Ratio: 2.47 GF Score: 79/100

Arcus Biosciences Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 07:30PM GMT
Release Date Price: $22.5 (+2.32%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Let's start. So welcome back, everyone, to the panel track. I'm Yigal Nochomovitz, I'm one of the biotech analysts at Citi. So this is the immuno-oncology panel. I think this is the first time I've done an IO panel recently. So welcome everyone. We have the CEO of Arcus, Terry Rosen, welcome Terry; Mark Lanasa, the CMO of Solid Tumors at BeiGene, welcome; and Theresa Lavallee, the Chief Development Officer at Coherus, welcome, Theresa.

We just recently launched coverage on BeiGene and Coherus. And of course, Terry and Arcus, we've spent many years. So for those less familiar, why don't we just kind of run down the line and just -- I know there's a lot to talk about, but just give a very high-level 2-minute elevator pitch on the pipeline and just what are the key focus with -- I was trying to emphasize the IO angle, given that's the topic of the day. So okay, Mark.

Mark Lanasa
BeiGene, Ltd. - Senior VP & Chief Medical Officer for Solid Tumors

Happy to be here today. So BeiGene, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot